Filing Details

Accession Number:
0000899243-21-034455
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-27 20:07:00
Reporting Period:
2021-08-27
Accepted Time:
2021-08-27 20:07:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1029142 Dynavax Technologies Corp DVAX Pharmaceutical Preparations (2834) 330728374
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657434 F. A. Andrew Hack C/O Bain Capital Life Sciences Investors
200 Clarendon Street
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-27 1,891,000 $0.00 10,415,000 No 4 C Indirect See footnotes
Common Stock Disposition 2021-08-27 2,000,000 $16.22 8,415,000 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 S Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2021-08-27 1,891 $0.00 1,891,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-08-12 No 4 C Indirect
Footnotes
  1. Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
  2. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
  3. Each share of Series B Convertible Preferred Stock was convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and had no expiration date. The Series B Convertible Preferred Stock was not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion. On August 27, 2021, the Bain Capital Life Sciences Entities converted an aggregate of 1,891 shares of Series B Convertible Preferred Stock into an aggregate of 1,891,000 shares of the Issuer's common stock.